Prediction of P-tau/Aβ42 in the cerebrospinal fluid with blood microRNAs in Alzheimer’s disease

[1] McKhann GM(2011)The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 263-269

[2] Knopman DS(2009)Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain Arch Neurol 66 382-389

[3] Chertkow H(2019)Multisite study of the relationships between antemortem [(11)C]PIB-PET Centiloid values and postmortem measures of Alzheimer’s disease neuropathology Alzheimers Dement 15 205-216

[4] Hyman BT(2020)Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders JAMA Neurol 77 955-965

[5] Jack CR(2016)CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis Lancet Neurol 15 673-684

[6] Kawas CH(2006)Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study Lancet Neurol 5 228-234

[7] Klunk WE(2018)A 2-step cerebrospinal algorithm for the selection of frontotemporal lobar degeneration subtypes JAMA Neurol 75 738-745

[8] Koroshetz WJ(2018)Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging Alzheimers Dement 14 1460-1469

[9] Manly JJ(2015)Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer’s disease from other dementias and healthy controls in the OPTIMA cohort J Alzheimers Dis 44 525-539

[10] Mayeux R(2019)Concordance between the assessment of Abeta42, T-tau, and P-T181-tau in peripheral blood neuronal-derived exosomes and cerebrospinal fluid Alzheimers Dement 15 1071-1080

[1] McKhann GM(2011)The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 263-269

[2] Knopman DS(2009)Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain Arch Neurol 66 382-389

[3] Chertkow H(2019)Multisite study of the relationships between antemortem [(11)C]PIB-PET Centiloid values and postmortem measures of Alzheimer’s disease neuropathology Alzheimers Dement 15 205-216

[4] Hyman BT(2020)Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders JAMA Neurol 77 955-965

[5] Jack CR(2016)CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis Lancet Neurol 15 673-684

[6] Kawas CH(2006)Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study Lancet Neurol 5 228-234

[7] Klunk WE(2018)A 2-step cerebrospinal algorithm for the selection of frontotemporal lobar degeneration subtypes JAMA Neurol 75 738-745

[8] Koroshetz WJ(2018)Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging Alzheimers Dement 14 1460-1469

[9] Manly JJ(2015)Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer’s disease from other dementias and healthy controls in the OPTIMA cohort J Alzheimers Dis 44 525-539

[10] Mayeux R(2019)Concordance between the assessment of Abeta42, T-tau, and P-T181-tau in peripheral blood neuronal-derived exosomes and cerebrospinal fluid Alzheimers Dement 15 1071-1080